Market Research Report
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Drugs in Development, 2021
|Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Drugs in Development, 2021|
Published: September 30, 2021
Global Markets Direct
Content info: 202 Pages
Delivery time: 1-2 business days
According to the recently published report 'Complement C5 - Drugs In Development, 2021'; Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) pipeline Target constitutes close to 43 molecules. Out of which approximately 39 molecules are developed by companies and remaining by the universities/institutes.
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Complement component 5 is a protein is encoded by the C5 gene. Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.
The report 'Complement C5 - Drugs In Development, 2021' outlays comprehensive information on the Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 13, 3, 5, 1, 16 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Immunology, Hematological Disorders, Gastrointestinal, Central Nervous System, Infectious Disease, Ophthalmology, Cardiovascular, Dermatology, Genito Urinary System And Sex Hormones, Musculoskeletal Disorders, Oncology, Other Diseases, Respiratory and Undisclosed which include indications Paroxysmal Nocturnal Hemoglobinuria, Myasthenia Gravis, Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), Neuromyelitis Optica (Devic's Syndrome), Coronavirus Disease 2019 (COVID-19) Pneumonia, Autoimmune Disorders, Chronic Inflammation, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Associated Acute Lung Injury, Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Kidney Disease (Nephropathy), Lupus Nephritis, Age Related Macular Degeneration, Bullous Pemphigoid, Dermatomyositis, Geographic Atrophy, Guillain-Barre Syndrome, Hidradenitis Suppurativa, IgA Nephropathy (Berger's Disease), Thrombotic Microangiopathy, Unspecified, Uveitis, Acute Lung Injury, Amyotrophic Lateral Sclerosis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Antiphospholipid Syndrome, Atopic Keratoconjunctivitis, Bacterial Sepsis, Cardiovascular Inflammation, Choroidal Neovascularization, Community Acquired Pneumonia, Fibrosis, Granulomatosis with Polyangiitis (Wegener's Granulomatosis), Hematuria, Hemorrhagic Shock, Intermediate Uveitis, Juvenile Macular Degeneration (Stargardt Disease), Liver Transplant Rejection, Lung Adenocarcinoma, Lung Disease, Microscopic Polyangiitis (MPA), Multiple Organ Failure (Multiple Organ Dysfunction Syndrome), Posterior Uveitis, Primary Progressive Multiple Sclerosis (PPMS), Pyoderma Gangrenosum, Rheumatoid Arthritis, Sepsis, Septic Shock, Sickle Cell Disease With Vaso-Occlusive Crisis, Squamous Cell Carcinoma, Subarachnoid Hemorrhage, Sudoriferous (Sweat) Gland Disorders, Trauma, Typical Hemolytic Uremic Syndrome (Shiga-Toxin Associated Hemolytic Uremic Syndrome) and Unspecified Ophthalmological Disorders.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.